You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 322 Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
322 Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2024

AbstractFullPdf
Nov 2020236037
Dec 20202607
Jan 20215408
Feb 202150011
Mar 202180019
Apr 20213407
May 202116013
Jun 2021009
Jul 2021004
Aug 2021007
Sep 2021009
Oct 202140032
Nov 202150023
Dec 202144010
Jan 202260011
Feb 20228009
Mar 2022114012
Apr 20228808
May 202292018
Jun 20225407
Jul 20224002
Aug 202236011
Sep 20225605
Oct 20223002
Nov 20221803
Dec 20222604
Jan 20234605
Feb 20234606
Mar 20231805
Apr 20232006
May 202328013
Jun 20231804
Jul 20231403
Aug 20235606
Sep 20234202
Oct 20234407
Nov 20233603
Dec 20236203
Jan 20242600
Feb 20242401
Mar 20242806
Total18320358